



Biotech Daily

Monday April 27, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: ATCOR UP 8%, ACTINOGEN DOWN 13%**
- * **CE MARK FOR AVITA'S EXPANDED RECELL BURNS TREATMENT**
- * **COGSTATE CLAIMS \$6m IN TEST CONTRACTS, 'BEST YEAR FOR SALES'**
- * **ONCOSIL AWARDED ISO CERTIFICATION**
- * **ST VINCENT'S 2015 FORUM: 'MEDICINE BEYOND PILLS & POTIONS'**

MARKET REPORT

The Australian stock market climbed 0.83 percent on Monday April 27, 2015 with the S&P ASX 200 up 49.4 points to 5,982.7 points, just 17.3 points short of the 6,000.0 point marker that seems to be exciting some people who like round aggregate numbers.

Eighteen of the Biotech Daily Top 40 stocks were up, 11 fell and 11 traded unchanged.

Atcor was the best, up two cents or 8.3 percent to 26 cents with 407,697 shares traded.

Circadian and Oncosil climbed more than six percent; Anteo and Reva rose more than five percent; Antisense was up four percent; Benitec, GI Dynamics, IDT, Impedimed and Osprey were up more than three percent; Avita and Psivida rose more than two percent; Bionomics, Living Cell, Sirtex and Starpharma were up one percent or more; with Cochlear, CSL and Nanosonics up by less than one percent.

Actinogen led the falls for the second trading day in a row, down 1.5 cents or 13.0 percent to 10 cents with 3.5 million shares traded.

Patrys lost 8.3 percent; Optiscan fell 5.1 percent; Cellmid, Compumedics and Uscom fell four percent or more; Prana and Medical Developments were down more than three percent; with Acrux, Admedus and Universal Biosensors down more than one percent.

AVITA MEDICAL

Avita says it has received Conformité Européenne (CE) mark for an enhanced version of its Recell device for the treatment of burns.

Avita said that the new Recell product could treat on up to 1,920cm² surface area, a six-fold greater coverage than previously possible from the first generation product.

The company said that the original Recell device could cover up to 320cm² and allowed clinicians to treat about 1.5 percent of an adult's total body surface area, and the new device was better aligned to meet grafting requirements of burn victims.

Last year, Avita said that the UK National Institute for Health and Care Excellence recommended Recell return to its original large area use (BD: Nov 13, 2014).

Avita said last November that the Medical Technologies Advisory Committee reviewed additional evidence and said that Recell was a "promising technology with potential to improve healing in acute burns, especially for patients with burns that need skin grafting", but cited insufficient evidence when they attempted to determine the most appropriate patient population for the Recell Spray-on Skin system and said that its expert clinical advice was that Recell might be most beneficial for treating large area full-thickness or deep partial-thickness burns requiring skin grafting.

In 2008, Clinical Cell Cultures merged with Visiomed to form Avita and then chief executive officer Dr Bill Dolphin said that Cellspray and Cellspray XP, which required expansion in a laboratory developed by Prof Fiona Woods for large acute burns, were "on the shelf" and the company would proceed with Recell for dermatology and cosmetic uses (BD: Jun 4, 2008).

Clinical Cell Cultures announced the original Recell CE mark approval in March 2005.

Today, Avita chief executive officer Adam Kelliher said the CE mark approval was "an important step in realizing the full potential of Avita's best-in-class regenerative product portfolio".

"Recell is now better positioned to address the needs of the burn patients and we look forward to commencing commercial activities across Europe, and a corresponding uptick in revenue," Mr Kelliher said.

Avita was up 0.2 cents or 2.7 percent to 7.7 cents.

COGSTATE

Cogstate says it will provide \$US4.9 million (\$A6.3 million) in cognition testing for a phase III depression trial program sponsored by an unnamed pharmaceutical company.

Cogstate said that it expected to recognize revenue of \$3.75 million from the contracts before June 30, 2015.

The company said that the total value of contracts signed in the financial year to date was \$US21.9 million, making it the "most successful financial year for sales contracts".

Cogstate said that the growth in the clinical trials business was "a result of changes made within the business to enhance business development activities and operational delivery".

The company said it had significantly increased business development resources for the clinical trials business, moving from a scientist-based peer-to-peer selling model to a formalized commercial business development team, leading to better identification and conversion of sales opportunities.

Cogstate said that the contracts in place would generate revenue of \$9.97 million for the six months to June 30, 2015.

The company said it expected a total of clinical trials contracts of \$29.82 million to be recognized over the coming five years.

Cogstate climbed 5.5 cents or 31.4 percent to 23 cents.

ONCOSIL MEDICAL

Oncosil says it has been awarded certification for the design, development and control of manufacture of a radioactive implantable medical device for oncology.

Oncosil said that the International Organization for Standardization (ISO) awarded ISO 13485:2012 and ISO 13485:2003, which were issued by the British Standards Institution demonstrating that the company had implemented a quality management system that conformed to world-wide medical device standards.

The company said that certification mean that it had met a key requirement for the Conformité Européenne (CE) mark under the European Union Active Implantable Medical Devices Directive for its localized radiation treatment for cancer.

Oncosil said that certification was accepted by most other major markets including the US, Canada, Japan and Australia.

Oncosil chief executive officer Daniel Kenny said the certification was “an important milestone on our commercialization pathway”.

“Our goal is to provide a commercially available treatment option for pancreatic and liver cancer patients globally and to explore use of our technology in other solid tumor indications in the future,” Mr Kenny said.

Oncosil was up half a cent or 6.1 percent to 8.7 cents with 8.2 million shares traded.

THE ST VINCENT'S INSTITUTE

Melbourne's St Vincent's Institute Forum says patron Prof Gustav Nossal will chair a discussion on the 21st Century “post-pills and potions” revolution in therapeutic medicine. The St Vincent's Institute said that the annual Forum, to be held on May 25, 2015, would bring together leaders in medicine, medical research and biotechnology to reflect upon the possibilities opened up by the therapeutic revolution.

The Institute said that 21st century “has seen ‘pills and potions’ relegated to the history books with the introduction of precision medicine, including the use of monoclonal antibodies and three-dimensional printed body part replacement to treat diseases such as Alzheimer's disease and arthritis”.

The Institute said that speakers at the Forum would include the University of Oxford's Prof Marc Feldmann, St Vincent's Hospital's Prof Peter Choong and Prof Michael Parker.

The Forum will be held at the Philippa Brazill Lecture Theatre, Daniel Mannix Building, Australian Catholic University, 12 Brunswick Street, Fitzroy, on May 25, 2015 at 5:45pm for 6:15pm. Refreshments will be served on arrival.

The Institute said the event was free of charge but registration was required by May 18, 2015 at: https://www.svi.edu.au/news/the_svi_forum_2015_beyond_pills.